|
1
|
Jarius S and Wildemann B: Aquaporin-4
antibodies (NMO-IgG) as a serological marker of neuromyelitis
optica: A critical review of the literature. Brain Pathol.
23:661–683. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vodopivec I, Matiello M and Prasad S:
Treatment of neuromyelitis optica. Curr Opin Ophthalmol.
26:476–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wingerchuk DM, Pittock SJ, Lucchinetti CF,
Lennon VA and Weinshenker BG: A secondary progressive clinical
course is uncommon in neuromyelitis optica. Neurology. 68:603–605.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kitley J, Leite MI, Nakashima I, Waters P,
McNeillis B, Brown R, Takai Y, Takahashi T, Misu T, Elsone L, et
al: Prognostic factors and disease course in aquaporin-4
antibody-positive patients with neuromyelitis optica spectrum
disorder from the United Kingdom and Japan. Brain. 135:1834–1849.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wingerchuk DM and Weinshenker BG:
Neuromyelitis optica: Clinical predictors of a relapsing course and
survival. Neurology. 60:848–853. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cabre P, González-Quevedo A, Bonnan M,
Saiz A, Olindo S, Graus F, Smadja D, Merle H, Thomas L and
Cabrera-Gomez JA: Relapsing neuromyelitis optica: Long term history
and clinical predictors of death. J Neurol Neurosurg Psychiatry.
80:1162–1164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watanabe S, Nakashima I, Misu T, Miyazawa
I, Shiga Y, Fujihara K and Itoyama Y: Therapeutic efficacy of
plasma exchange in NMO-IgG-positive patients with neuromyelitis
optica. Mult Scler. 13:128–132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Miguel MP, Fuentes-Julián S,
Blázquez-Martínez A, Pascual CY, Aller MA, Arias J and
Arnalich-Montiel F: Immunosuppressive properties of mesenchymal
stem cells: Advances and applications. Curr Mol Med. 12:574–591.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eckert MA, Vu Q, Xie K, Yu J, Liao W,
Cramer SC and Zhao W: Evidence for high translational potential of
mesenchymal stromal cell therapy to improve recovery from ischemic
stroke. J Cereb Blood Flow Metab. 33:1322–1334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Bowles AC, Semon JA, Scruggs BA,
Zhang S, Strong AL, Gimble JM and Bunnell BA: Transplantation of
autologous adipose stem cells lacks therapeutic efficacy in the
experimental autoimmune encephalomyelitis model. PLoS One.
9:e850072014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Chai J, Shen C, Han Y and Sun T:
Human umbilical cord-derived mesenchymal stem cells differentiate
into epidermal-like cells using a novel co-culture technique.
Cytotechnology. 66:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zacharek A, Shehadah A, Chen J, Cui X,
Roberts C, Lu M and Chopp M: Comparison of bone marrow stromal
cells derived from stroke and normal rats for stroke treatment.
Stroke. 41:524–530. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cohen JA: Mesenchymal stem cell
transplantation in multiple sclerosis. J Neurol Sci. 333:43–49.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Akabawy G and Rashed LA: Beneficial
effects of bone marrow-derived mesenchymal stem cell
transplantation in a non-immune model of demyelination. Ann Anat.
198:11–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N,
Yu C, Su L, Zhang R, Shen Y, et al: Impact of autologous
mesenchymal stem cell infusion on neuromyelitis optica spectrum
disorder: A pilot, 2-year observation study. CNS Neurosci Ther.
22:677–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Belotti D, Capelli C, Resovi A, Introna M
and Taraboletti G: Thrombospondin-1 promotes mesenchymal stromal
cell functions via TGFβ and in cooperation with PDGF. Matrix Biol.
55:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papadopoulos N and Lennartsson J: The
PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 62:75–88.
2018. View Article : Google Scholar
|
|
19
|
Chen W, Baylink DJ, Brier-Jones J, Neises
A, Kiroyan JB, Rundle CH, Lau KH and Zhang XB: PDGFB-based stem
cell gene therapy increases bone strength in the mouse. Proc Natl
Acad Sci USA. 112:E3893–E3900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Solchaga LA, Bendele A, Shah V, Snel LB,
Kestler HK, Dines JS and Hee CK: Comparison of the effect of
intra-tendon applications of recombinant human platelet-derived
growth factor-BB, platelet-rich plasma, steroids in a rat achilles
tendon collagenase model. J Orthop Res. 32:145–150. 2014.
View Article : Google Scholar
|
|
21
|
Lennon VA, Wingerchuk DM, Kryzer TJ,
Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I and Weinshenker
BG: A serum autoantibody marker of neuromyelitis optica:
Distinction from multiple sclerosis. Lancet. 364:2106–2112. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao J, Yang R, Biswas S, Qin X, Zhang M
and Deng W: Mesenchymal stem cells and induced pluripotent stem
cells as therapies for multiple sclerosis. Int J Mol Sci.
16:9283–9302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greco R, Bondanza A, Vago L, Moiola L,
Rossi P, Furlan R, Martino G, Radaelli M, Martinelli V, Carbone MR,
et al: Allogeneic hematopoietic stem cell transplantation for
neuromyelitis optica. Ann Neurol. 75:447–453. 2014. View Article : Google Scholar
|
|
24
|
Matiello M, Pittock SJ, Porrata L and
Weinshenker BG: Failure of autologous hematopoietic stem cell
transplantation to prevent relapse of neuromyelitis optica. Arch
Neurol. 68:953–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilkins A, Kemp K, Ginty M, Hares K,
Mallam E and Scolding N: Human bone marrow-derived mesenchymal stem
cells secrete brain-derived neurotrophic factor which promotes
neuronal survival in vitro. Stem Cell Res. 3:63–70. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cramer SC, Sur M, Dobkin BH, O'Brien C,
Sanger TD, Trojanowski JQ, Rumsey JM, Hicks R, Cameron J, Chen D,
et al: Harnessing neuroplasticity for clinical applications. Brain.
134:1591–1609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH
and Bang OY: STARTING collaborators: A long-term follow-up study of
intravenous autologous mesenchymal stem cell transplantation in
patients with ischemic stroke. Stem Cells. 28:1099–1106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Connick P, Kolappan M, Crawley C, Webber
DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ,
et al: Autologous mesenchymal stem cells for the treatment of
secondary progressive multiple sclerosis: An open-label phase 2a
proof-of-concept study. Lancet Neurol. 11:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park HJ, Shin JY, Lee BR, Kim HO and Lee
PH: Mesenchymal stem cells augment neurogenesis in the
subventricular zone and enhance differentiation of neural precursor
cells into dopaminergic neurons in the substantia nigra of a
parkinsonian model. Cell Transplant. 21:1629–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Danielyan L, Schäfer R, von
Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati
A, Klopfer T, Schaumann F, Schmid B, et al: Therapeutic efficacy of
intranasally delivered mesenchymal stem cells in a rat model of
Parkinson disease. Rejuvenation Res. 14:3–16. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu Z, Ye D, Qian L, Zhu L, Wang C, Guan D,
Zhang X and Xu Y: Human umbilical cord mesenchymal stem cell
therapy on neuromyelitis optica. Curr Neurovasc Res. 9:250–255.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zaiss DMW, Gause WC, Osborne LC and Artis
D: Emerging functions of amphiregulin in orchestrating immunity,
inflammation, and tissue repair. Immunity. 42:216–226. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jeon H and Boo YC: Senescent endothelial
cells are prone to TNF-α-induced cell death due to expression of
FAS receptor. Biochem Biophys Res Commun. 438:277–282. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ols ML, Cullen JL, Turqueti-Neves A, Giles
J and Shlomchik MJ: Dendritic cells regulate extrafollicular
autoreactive B cells via T cells expressing Fas and Fas ligand.
Immunity. 45:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cruz AC, Ramaswamy M, Ouyang C, Klebanoff
CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R,
et al: Fas/CD95 prevents autoimmunity independently of lipid raft
localization and efficient apoptosis induction. Nat Commun.
7:138952016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ikezawa K, Hikita H, Shigekawa M, Iwahashi
K, Eguchi H, Sakamori R, Tatsumi T and Takehara T: Increased Bcl-xL
expression in pancreatic neoplasia promotes carcinogenesis by
inhibiting senescence and apoptosis. Cell Mol Gastroenterol
Hepatol. 4:185–200.e181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aouacheria A, Baghdiguian S, Lamb HM,
Huska JD, Pineda FJ and Hardwick JM: Connecting mitochondrial
dynamics and life-or-death events via Bcl-2 family proteins.
Neurochem Int. 109:141–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang Y and Dreyfus CF: The role of growth
factors as a therapeutic approach to demyelinating disease. Exp
Neurol. 283:531–540. 2016. View Article : Google Scholar : PubMed/NCBI
|
